Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DRD2 RNAi
- Development stage
- Preclinical
- Lead developer
- McGill University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intrathecal, Intraperitoneal, Intradermal, Intratumoral
01
Overview
DRD2 RNAi refers to the use of RNA interference (RNAi) technology, such as small interfering RNA (siRNA) or short hairpin RNA (shRNA), to specifically silence the expression of the dopamine receptor D2 (DRD2). In the context of oncology research, particularly pancreatic ductal adenocarcinoma (PDAC), DRD2 has been identified as a key modulator of cancer pathways. Inhibiting DRD2 via RNAi has been shown to hamper the proliferative and invasive capacities of pancreatic cancer cells by modulating cAMP and endoplasmic reticulum stress pathways. While primarily used as a research tool to validate DRD2 as a therapeutic target, this approach demonstrates the potential for DRD2-targeted therapies in treating primary and metastatic tumors.
- Other names
- DRD2 siRNADRD-2 siRNADRD 2 siRNADRD2 shRNADRD-2 shRNADRD 2 shRNAdopamine receptor D2 RNA interference
02
Targets
DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on DRD2 RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DRD2 RNAi.